Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 Dec 25:8:89-92.
doi: 10.1016/j.jdcr.2020.12.025. eCollection 2021 Feb.

B-cell lymphoma 2 inhibitor venetoclax treatment of a patient with cutaneous T-cell lymphoma

Amber Loren O King  1 , Fatima N Mirza  1 , Julia M Lewis  1 , Kacie R Carlson  1 , Scott Huntington  2 , Francine M Foss  2 , Michael Girardi  1
Affiliations
Case Reports

B-cell lymphoma 2 inhibitor venetoclax treatment of a patient with cutaneous T-cell lymphoma

Amber Loren O King et al. JAAD Case Rep. .
No abstract available

Keywords: BCL-2; BCL-2, B-cell lymphoma 2; CTCL; CTCL, cutaneous T-cell lymphoma; NHL, non-Hodgkin lymphoma; Sézary syndrome; TCR, T-cell receptor; TLS, tumor lysis syndrome; venetoclax.

PubMed Disclaimer

Conflict of interest statement

None disclosed.

Figures

Fig 1
Fig 1
Representative patient lesions (A) prior to beginning and (B) at the conclusion of the 6-month venetoclax clinical trial.
Fig 2
Fig 2
Graphic representation of absolute counts (cells/μL) of abnormal lymphocytes, CD4+CD7– cells, and CD4+CD26– cells over the venetoclax treatment span.
Fig 3
Fig 3
Dose-response curves of isolated malignant cutaneous T-cell lymphoma cells to venetoclax in vitro. Prior to initiation and 28 weeks after venetoclax therapy, malignant T cells were isolated from the patient and exposed to gradient concentrations of venetoclax in vitro. Cell viability was measured after 72 hours by CellTiter Glo luminescence assay.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Argnani L., Broccoli A., Zinzani P.L. Cutaneous T-cell lymphomas: focusing on novel agents in relapsed and refractory disease. Cancer Treat Rev. 2017;61:61–69. - PubMed
    1. D' Aguanno S., Del Bufalo D. Inhibition of anti-apoptotic Bcl-2 proteins in preclinical and clinical studies: current overview in cancer. Cells. 2020;9(5):1287. - PMC - PubMed
    1. Pan R., Hogdal L.J., Benito J.M. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov. 2014;4(3):362–375. - PMC - PubMed
    1. Yumeen S., Mirza F.N., Lewis J.M. JAK inhibition synergistically potentiates BCL2, BET, HDAC, and proteasome inhibition in advanced CTCL. Blood Adv. 2020;4(10):2213–2226. - PMC - PubMed
    1. Cyrenne B.M., Lewis J.M., Weed J.G. Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients. Blood. 2017;130(19):2073–2083. - PMC - PubMed

Publication types

LinkOut - more resources